Zydus Lifesciences Ltd
General
Total Cases35
Active Cases11
Patents26
Ratings
Experience
Grade
Trend
DCT
L4
E
PTAB
--
--
--
CAFC
L4
B
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
---|---|---|
10/30/24 | NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc.'s and Zydus Lifesciences Limited's Objections and Responses to Plaintiffs' Notice of Deposition of Defendant Zydus Under Federal Rule of Civil Procedure 30(b)(6) filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc..(Stombaugh, Alexis) (Entered: 10/30/2024) | |
10/30/24 | MEMORANDUM AND ORDER: The Parties Motions for Claim Construction (D.I. [110] and D.I. [111] ) are GRANTED. (See Order for further details.) Ordered by Judge Joseph F. Bataillon on 10/30/2024. (vfm) (Entered: 10/30/2024) | |
10/29/24 | SO ORDERED, D.I. [361] Stipulation and Order Regarding Sample Chain of Custody filed by Astellas Ireland Co., Ltd., Astellas Pharma Inc., Astellas Pharma Global Development, Inc. Ordered by Judge Christopher J. Burke on 10/28/2024. (smg) (Entered: 10/29/2024) | |
10/28/24 | STIPULATION and [Proposed] Order Regarding Sample Chain of Custody by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Joyce, Alexandra) (Entered: 10/28/2024) | |
10/24/24 | NOTICE OF SERVICE of (1) Lupin Ltd. and Lupin Pharmaceuticals, Inc.'s Responses to Plaintiffs' Fourth Set of Interrogatories (Nos. 11-22); (2) Lupin Ltd. and Lupin Pharmaceuticals, Inc.'s Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-15); and (3) Lupin Ltd. and Lupin Pharmaceuticals, Inc.'s Responses to Plaintiffs' [sic] Second Set of Requests for Production of Documents and Things (Nos. [sic] 8-22) filed by Lupin Ltd., Lupin Pharmaceuticals, Inc..(Haney, Megan) (Entered: 10/24/2024) | |
10/23/24 | NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Lupin Limited and Lupin Pharmaceuticals, Inc.'s Third Set of Requests for Production (Nos. 3-6), (2) Plaintiffs' First Supplemental Objections and Responses to Defendants' Joint Interrogatories (Nos. 4-5), (3) Plaintiffs' Objections and Responses to Defendants' Joint Third of Interrogatories (Nos. 6-15), (4) Plaintiffs' Objections and Responses to Defendants' Joint Third Set of Requests for Production (Nos. 13-25) filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc..(Silver, Daniel) (Entered: 10/23/2024) | |
10/23/24 | NOTICE OF SERVICE of 1) Defendants Zydus Pharmaceuticals (USA) Inc.'s and Zydus Lifesciences Limited's Objections and Responses to Plaintiffs' Second Set of Requests to Zydus for the Production of Documents and Things (Nos. 8-23); 2) Defendants Zydus Pharmaceuticals (USA) Inc.'s and Zydus Lifesciences Limited's Objections and Responses to Plaintiffs' Fourth Set of Interrogatories to Zydus (Nos. 11-23); and 3) Defendants Zydus Pharmaceuticals (USA) Inc.'s and Zydus Lifesciences Limited's Objections and Responses to Plaintiffs' First Set of Requests for Admission to Zydus (Nos. 1-15) filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc..(Stombaugh, Alexis) (Entered: 10/23/2024) | |
10/22/24 | SO ORDERED, D.I. [355] Stipulation and Order to Amend the Case Schedule filed by Astellas Ireland Co., Ltd., Astellas Pharma Inc., Astellas Pharma Global Development, Inc. (Fact Discovery completed by 12/20/2024, Opening Expert Reports due by 2/7/2025, Rebuttal Expert Reports due by 3/14/2025, Expert Discovery due by 5/12/2025, Proposed Pretrial Order due by 8/28/2025. See Order for further deadlines.) Signed by Judge Christopher J. Burke on 10/22/2024. (smg) (Entered: 10/22/2024) | |
10/22/24 | ORDER: Defendants' objections (D.I. [326] ) to the magistrate judges order are overruled, and the Magistrate Judges oral order (D.I. 311) is affirmed in all respects. (See Order for further details) Signed by Judge Joseph F. Bataillon on 10/21/2024. (mpb) (Entered: 10/22/2024) | |
10/18/24 | STIPULATION and [Proposed] Order to Amend the Case Schedule by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Silver, Daniel) (Entered: 10/18/2024) |